Treatment of overactive bladder with sodium chondroitin sulphate;Der einsatz von natrium-chondroitinsulfat bei der behandlung der "überaktiven blase"

Zentralblatt fur Gynakologie

Volumn 128, Issue 6, 2006, Pages 336-340

  Gauruder Burmester, Annett ^a,b   Wildt, B ^a   Tunn, R ^a  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

^b St Hedwig Hospital   (Germany)

Author keywords

Glycosaminoglycan layer; Interstitial cystitis; Overactive bladder; Sodium chondroitin sulphate

Indexed keywords

CHONDROITIN SULFATE; TOLTERODINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTOSCOPY; GYNECOLOGICAL EXAMINATION; HUMAN; MICTURITION; NOCTURIA; OVERACTIVE BLADDER; QUALITY OF LIFE; ULTRASOUND; URODYNAMICS;

CHOLINERGIC ANTAGONISTS; CHONDROITIN SULFATES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 33846238846     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-933378     Document Type: Article

References (29)

1. Miller JJ, Sand PK. Diagnosis and treatment of overactive bladder. Minerva Ginecol 2005; 57: 501-520
2. AWMF-Leitlinien-Register. Nr. 043/038. Entwicklungsstufe: 1, online 3 Hertle L, Oberpenning F, Ophoven AV. Deutsches Ärzteblatt 2002; 99: A-204/B-163/C-159
3. Brinkmann OA, Hertle L. The pathogenesis of interstitial cystitis - manifold conjecutres but yet an unsolved etiology. Urologe 2000; 39: 520-526
4. Dieter J, Miller K. Praxis der Urologie. Bd. 2. Thieme, 1994
5. Gimbel H, Zobbe V, Andersen BJ, Sorensen HC, Topftager-Larsen K, Sidenius K, Moller N, Madsen EM, Vejtorp M, Clausen H, Rosgaard A, Villumsen J, Gluud C, Ottesen BS, Tabor A. Lower urinary tract symptoms after total and subtotal hysterectomy: results of a randomized controlled trial. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 257-262
6. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J Urol 1999; 161: 549-552
7. Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg Jr L. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 1999; 161: 549-552
8. Ruggieri Sr MR, Bravermann AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174: 1743-1748
9. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 2005; 174: 2032-2036
10. Loch A, Stein U. Interstitielle Zystitis - Aktuelle Aspekte in der Diagnostik und Therapie. Urologe A 2005; 43: 1135-1146
11. Wein AJ. Pilot study of the feasibility of in-office bladder distention using electromotive drug administration (EMDA). J Urol 2005; 174: 2247-2248
12. Amaro JL, Gameiro MO, Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 355-358
13. Russell AL, Grigo HM, Joseph NS, Niu J, Bachmann G. Evaluation the performance of pelvic floor exercises in women with urinary incontinence. J Reprod Med 2005; 50: 529-532
14. Rackley R, Abdelmalak J. Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 2004; 5: 381-388
15. Ghei M, Maraj BH, Miller R, Nathan S, O'sullivan C, Fowler CJ, Shah PJ, Malone-Lee J. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005; 174: 1873-1877
16. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171 (6 Pt. 1): 2128-2137
17. Hurst RE, Roy JB, Parsons CL. The role of glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. In: Sant G (ed). Interstitial Cystits. Lippincott-Raven Publishers, Philadelphia 1997; 93-100
18. Hurst RE, Roy JB, Min KW, Veltri W, Merley G, Patton K, Shakelford DL, Stein P, Parsons CL. A deficit of chondroitinsulfate proteoglycans on bladder urothelium in interstitial cystitis. Urology 1996; 48: 817-821
19. Hurst RE. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 1994; 12: 3-10
20. Gauruder-Burmester A, Kölbl H, Peruccini D, Peschers U, Petri E, Reisenauer C, Tamussion K, Tunn R. Descensus genitalis und Harninkontinenz. AWM-Leitlinien-Register Nr. 015/006. Entwicklungsstufe 1
21. Schüssler B, Laycock J, Norton P, Stanton S. Pelvic Floor Re-ecducation - Principles and Practice. Springer 1994; 44-45
22. Freiha FS, Stamey TA. Cystolysis: a procedure for the selective denervation of the bladder. J Urol 1980; 123: 360-363
23. Ophoven AV, Hertle L. Long-term results of amitriptyline treatment of interstitial cystitis. J Urol 2005; 174: 1837-1840
24. Chapple C. Darifenacin is effective in improving the major symptoms of overactive bladder: A pooled analysis of phase III studies. Eur Urol Suppl 2004; 3: A513
25. Andersson KE. Overactive bladder-pharmacological aspects. Scand J Urol Nephrol Suppl 2002; 210: 72-81
26. Riazimand SH, Mense S. Interaction between neurotransmitter antagonists and effects of sacral neuromodulation in rats with chronically hyperactive bladder. BJU Int 2005; 96: 900-908
27. Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis. Urology 2005; 66: 494-499
28. Appell RA. Surgery for the treatment of overactive bladder. Urology 1998; 51 (2 A Suppl): 27-29
29. Steinhoff G. The efficacy of chondroitin sulphate in treating interstitial cystitis. Eur Urol Suppl 2003; 2: 14-16